Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Limited (NYSE:TEVA), agreed to serve as the stalking-horse bidder for substantially all assets of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) and certain affiliates through a court-supervised Chapter 11 auction. Teva Pharmaceutical Industries Limited (NYSE:TEVA) is the parent of the bidder and guarantor of the milestone-payment obligations. The […]

Teva Ukraine says a Russian attack struck its warehouse twice, with no employees injured; The pharmaceutical company is assessing the damage while working to prevent disruptions to medicine supplies for Ukrainian patients

2026-09-04. The following slide deck was published by Teva Pharmaceutical Industries Limited in conjunction with this event.

S&P; Global Ratings upgraded Teva Pharmaceuticals' credit rating to BBB- due to improved financial p

Teva Pharmaceutical Industries received a boost as UBS reaffirmed its "Buy" rating and raised the price target to $48, up from $36.62. This follows positive Phase 2a clinical trial results for TEV '408, a drug showing significant prevention of intestinal damage in celiac disease patients with good safety. The company’s low implied volatility also signals potential stock gains based on historical trends. These developments highlight Teva's promising growth and new treatment prospects beyond current gluten-free diets.